The treatment of small lymphocytoma (SLL) depends on the clinical staging symptoms and disease activity. Small lymphocytoma (SLL) and chronic lymphocytic leukemia (CLL) are different manifestations of the same disease and their treatment is essentially the same. It consists of two phases: follow-up observation and drug treatment. 1. Small lymphocytic lymphoma is a kind of slow-progressing B-cell proliferative tumor with a chronic inert course, and studies have shown that early treatment does not prolong the survival of patients, and early patients do not need to be treated, and regular review is sufficient. 2. When there are such symptoms as progressive splenomegaly or pain in the splenic region, weight loss of ≥10%, extreme fatigue, fever (38℃) for more than 2 weeks, night sweats, etc., it indicates that the disease is highly active and treatment should be started. Treatment includes chemotherapy (nitrogen mustard phenylbutyrate, fludarabine, glucocorticoids, etc.), immunotherapy (rituximab), chemoimmunotherapy (rituximab + fludarabine), and hematopoietic stem cell transplantation. Tumor treatment is an extremely complicated and professional process. Even for the same disease, patients with different physical conditions and different stages of the disease have different treatment methods, so standardized treatment should be carried out under the guidance of doctors in order to strive for a good prognosis. The above drugs need to be used under the guidance of doctors.